The exercise price was DKK 224.40 per share for 4,163 of new shares and DKK 90.70 per share for 288,345 of new shares. The ...

European shares European shares were higher on Monday as investors reacted to U.S. President Donald Trump delaying the roll ...

Zealand Pharma’s financial position has been significantly strengthened by the Roche partnership. As of March 2025, the company reported a cash position of DKK 8,544 million. Including the DKK ...

Copenhagen, Denmark, March 12, 2025 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based ...

Shares for Zealand Pharma rose by over 17% on Friday, after the Danish biotech firm announced positive trial results for petrelintide, a new weight loss drug the company said could compete against ...

Company announcement – No. 33 / 2024 Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 900 million ...

CEO Adam Steensberg emphasized 2024 as a transformational year for Zealand Pharma, highlighting significant clinical ...

COPENHAGEN, April 24 (Reuters) - Danish biotechnology company Zealand Pharma (ZELA.CO), opens new tab said on Thursday it had enrolled the first patient in a mid-stage trial with its weight-loss ...

Zealand Pharma A/S ADR advanced stock charts by Barron's. View ZLDPY historical stock data and compare to other stocks, and exchanges.

Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion under an agreement to co-develop a weight-loss treatment as the companies double down on ...

Zealand Pharma A/S is a Copenhagen, Denmark based commercial-stage biopharmaceutical concern focused on the development of peptide-based medicines for the treatment of a plethora of diseases ...

COPENHAGEN, Aug 15 (Reuters) - Denmark's Zealand Pharma (ZELA.CO), opens new tab is set to start talks in the second half of this year with other pharmaceutical companies for potential ...